In the BioHarmony Drug Report Database
Fluciclovine (18f)
Axumin (fluciclovine f18) is a small molecule pharmaceutical. Fluciclovine f18 was first approved as Axumin on 2016-05-27. It has been approved in Europe to treat prostatic neoplasms and radionuclide imaging. Axumin’s patents are valid until 2035-12-30 (FDA).
Trade Name
|
Axumin |
|---|---|
Common Name
|
fluciclovine f18 |
ChEMBL ID
|
CHEMBL3707267 |
Indication
|
prostatic neoplasms, radionuclide imaging |
Drug Class
|
Vinca alkaloids |
Image (chem structure or protein)